Sigyn Therapeutics (SIGY) Share-based Compensation (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Share-based Compensation of $50000.0 for Q3 2025, little changed sequentially from $50000.0 in Q2 2025, and up 33.33% YoY from $37500.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Share-based Compensation (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $50000.0 in Q3 2025.
- Quarterly Share-based Compensation rose 33.33% year-over-year to $50000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $187500.0 (down 13.02% YoY) and the FY2024 annual result came in at $150000.0, down 30.41% from the prior year.
- Share-based Compensation held at $50000.0 in Q3 2025 per SIGY's latest filing, from $50000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $103058.0 in Q4 2023 and troughed at $37500.0 in Q1 2023.
- A 4-year average of $50977.2 and a median of $37600.0 in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2024: Share-based Compensation soared 403.55% in 2021, then sank 63.61% in 2024.
- Over 4 years, Share-based Compensation stood at $37600.0 in 2021, then surged by 174.09% to $103058.0 in 2023, then slumped by 63.61% to $37500.0 in 2024, then jumped by 33.33% to $50000.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $50000.0, $50000.0, and $50000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 37,500.00 |
| Dec 31, 2024 | 37,500.00 |
| Sep 30, 2024 | 37,500.00 |
| Sep 30, 2024 | 37,500.00 |
| Jun 30, 2024 | 37,500.00 |
| Jun 30, 2024 | 37,500.00 |
| Mar 31, 2024 | 37,500.00 |
| Mar 31, 2024 | 37,500.00 |
| Dec 31, 2023 | 103,058.00 |
| Dec 31, 2023 | 103,058.00 |
| Sep 30, 2023 | 37,500.00 |
| Sep 30, 2023 | 37,500.00 |
| Jun 30, 2023 | 37,500.00 |
| Jun 30, 2023 | 37,500.00 |